The Role of Brain Penetrant BTK Inhibitors to Improve Outcomes in Patients with Multiple Sclerosis
CE Symposium in Conjunction with the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)
Wednesday, October 27th, 2021
7:00 – 8:00 am Eastern Time
Rosen Shingle Creek Hotel
Panzacola H Ballroom
9939 Universal Blvd
Orlando, Florida 32819
Neurologists, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis
This interactive CME/CE program will highlight the important emerging role of Bruton’s tyrosine kinase (BTK) inhibitors as the first brain penetrant disease modifying therapy that offers opportunities to improve neuroinflammation and neurodegeneration. The expert faculty, led by Fred D. Lublin, MD, will first provide an overview of the BTK inhibitor science. Following, current clinical trial data regarding the safety and efficacy of BTK inhibitors will be analyzed, along with the clinical implications for the multiple sclerosis patient. The faculty will conclude with a discussion of best practices for shared decision making from an interprofessional perspective to improve patient outcomes and quality of life.
I. BTK Inhibitor Science: Adaptive and Innate Immunity, Neuroinflammation and Neurodegeneration – Benjamin Greenberg, MD
II. Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Jiwon Oh, MD
III. Clinician/Patient Decision Making for Newer Therapeutics – Lessons Learned and Applied –Amy Perrin Ross, APN, MSN, CNRN, MSCN
IV. Interactive Panel Discussion – Fred D. Lublin, MD and Expert Faculty
- Review brain penetrating BTK inhibitor science, including neuroinflammation and neurodegeneration, as a therapeutic target to improve outcomes in patients with MS
- Analyze the current clinical trial data on the efficacy and safety of novel BTK inhibitors
- Utilize the comprehensive care team to apply treatment strategies for the application of BTK inhibitors and newer disease-modifying therapeutics to manage patients with MS
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
Jiwon Oh, MD
Assistant Professor, Division of Neurology
University of Toronto
Toronto, Ontario, Canada
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Oak Brook, Illinois
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™.
AcademicCME designates this live material for a maximum of 1.0 CNE Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-015-L04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300.
This activity has been supported by an independent educational grant from Sanofi Genzyme
Provided by AcademicCME
*This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.
*Further details regarding how to tune in to this live symposium will be emailed to the address used to register prior to the event.
For more information, feel free to check back to this page closer to October, 2021 or follow @academiccme on Twitter for real-time updates. You can also email [email protected] with any questions.